The FDA's grant of a seven-year orphan drug exclusivity for Nefecon significantly enhances Calliditas Therapeutics' competitive position in the market for treatments targeting primary IgAN. This exclusivity until December 2030 secures Calliditas a temporary monopoly on the treatment, potentially leading to increased sales and market penetration. The approval for a new indication also highlights the drug's efficacy and safety, likely boosting investor confidence and potentially leading to a short-term increase in CALT's stock price.